|Bid||0.00 x 900|
|Ask||0.00 x 800|
|Day's range||119.00 - 121.68|
|52-week range||105.36 - 142.60|
|Beta (5Y monthly)||0.70|
|PE ratio (TTM)||29.79|
|Earnings date||18 Apr 2022 - 22 Apr 2022|
|Forward dividend & yield||1.88 (1.53%)|
|Ex-dividend date||13 Jan 2022|
|1y target est||144.58|
It cannot be recorded or rebroadcast without Abbott's expressed written permission. With me today are Robert Ford, chairman and chief executive officer; and Bob Funck, executive vice president, finance and chief financial officer. Abbott cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements.
Abbott's (ABT) COVID-19 testing-related sales in Q4 increased on demand for BinaxNOW, Panbio and ID NOW rapid testing platforms.
Abbott (ABT) delivered earnings and revenue surprises of 11.86% and 8.52%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?